Drug:
Reaction: PRODUCT DOSE OMISSION ISSUE
20250101 - 20251231
No. 201 - 300
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 201 | 25135689 |
US |
43 | 1 |
Limb operation, Product dose omission issue, |
||||
TOFACITINIB, |
||||
| 202 | 25135775 |
CA |
2 | |
Product dose omission issue, Device deployment issue, Off label use, |
||||
GUSELKUMAB, |
||||
| 203 | 25135828 |
CA |
78 | 2 |
Abdominal pain upper, Anaemia, Aspiration, Asthenia, Asthma, Blood calcium increased, Blood creatinine increased, Blood test abnormal, Bronchiectasis, Bronchopulmonary aspergillosis allergic, Constipation, Cough, Drug hypersensitivity, Drug ineffective, Dyspnoea, Fatigue, Gastrooesophageal reflux disease, General physical health deterioration, Haemoptysis, Headache, Hypoxia, Liver function test increased, Lower respiratory tract infection, Lung opacity, Musculoskeletal stiffness, Obstructive airways disorder, Oedema peripheral, Pain, Pleural effusion, Pleuritic pain, Pneumonia, Pulmonary fibrosis, Pulmonary mass, Pyrexia, Rales, Sputum discoloured, Total lung capacity decreased, Transaminases increased, Tremor, Upper respiratory tract infection, Wheezing, Product dose omission issue, |
||||
MONTELUKAST SODIUM, MONTELUKAST SODIUM, MONTELUKAST SODIUM, MONTELUKAST SODIUM, MOMETASONE FUROATE, MOMETASONE FUROATE, MOMETASONE FUROATE, MOMETASONE FUROATE, MONTELUKAST SODIUM, MONTELUKAST, MONTELUKAST SODIUM, MONTELUKAST, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, ACETAMINOPHEN, ACETAMINOPHEN ORAL SOLUTION, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, ACETAMINOPHEN, DIPHENHYDRAMINE HCL, IPRATROPIUM BROMIDE, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, BISACODYL, BISACODYL SUPPOSITORIES, BISCODYL, BISACODYL, BISACODYL SUPPOSITORIES, BISCODYL, BISACODYL, BISACODYL SUPPOSITORIES, BISCODYL, BISACODYL, BISACODYL SUPPOSITORIES, BISCODYL, BISACODYL, BISACODYL SUPPOSITORIES, BISCODYL, CANDESARTAN, DEXLANSOPRAZOLE, FORMOTEROL FUMARATE, FORMOTEROL FUMARATE DIHYDRATE, FORMOTEROL FUMARATE, FORMOTEROL FUMARATE DIHYDRATE, NITROGLYCERIN, NITROGLYCERIN, EFINACONAZOLE, EFINACONAZOLE, EFINACONAZOLE, LANSOPRAZOLE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, MOMETASONE, NITROGLYCERIN, MEPOLIZUMAB, MEPOLIZUMAB, OMALIZUMAB, OMALIZUMAB, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PANTOPRAZOLE, PRAMIPEXOLE, PRAMIPEXOLE, PRAMIPEXOLE, PRAMIPEXOLE, PREGABALIN, PREGABALIN, LANSOPRAZOLE, LANSOPRAZOLE, LANSOPRAZOLE, LANSOPRAZOLE, PYRILAMINE MALEATE, PYRILAMINE MALEATE, PYRILAMINE MALEATE, QUETIAPINE FUMARATE, QUETIAPINE, QUETIAPINE FUMARATE, QUETIAPINE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, RANITIDINE HYDROCHLORIDE, RISEDRONATE SODIUM, ROSUVASTATIN CALCIUM, ROSUVASTATIN CALCIUM, ALBUTEROL SULFATE, ALBUTEROL, ALBUTEROL SULFATE, ALBUTEROL, SENNA LEAF, SENNOSIDES, SENNOSIDES, SENNOSIDES, STANDARDIZED SENNA CONCENTRATE, STANDARDIZED SENNA CONCENTRATE, STANDARDIZED SENNA CONCENTRATE, STANDARDIZED SENNA CONCENTRATE, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE, TIOTROPIUM BROMIDE, SIMVASTATIN, LEVOTHYROXINE SODIUM, ALBUTEROL SULFATE, |
||||
| 204 | 25135917 |
US |
42 | 1 |
Dysentery, Ill-defined disorder, Post-acute COVID-19 syndrome, Blood testosterone decreased, Illness, Depressed mood, Fatigue, Asthenia, Insomnia, Decreased appetite, Brain fog, Impaired work ability, Product dose omission issue, Product availability issue, Inappropriate schedule of product administration, |
||||
CHORIOGONADOTROPIN ALFA, |
||||
| 205 | 25135934 |
CA |
83 | 2 |
Pathological fracture, Product dose omission issue, |
||||
ABATACEPT, |
||||
| 206 | 25136009 |
GB |
4 | 2 |
Anxiety, Product dose omission issue, Device defective, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 207 | 25136048 |
US |
78 | 1 |
Knee arthroplasty, Colitis ulcerative, Device issue, Paraesthesia, Product dose omission issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 208 | 25136088 |
US |
41 | 1 |
Device defective, Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 209 | 25136124 |
US |
71 | 2 |
Product dose omission issue, |
||||
| 210 | 25136151 |
US |
75 | 2 |
Product dose omission issue, |
||||
| 211 | 25136160 |
US |
||
Hospitalisation, Influenza, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 212 | 25136308 |
US |
54 | 1 |
Impaired gastric emptying, Localised infection, Skin laceration, Product dose omission issue, |
||||
ABALOPARATIDE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, BACLOFEN, BUSPIRONE HYDROCHLORIDE, CARVEDILOL, FINASTERIDE, FUROSEMIDE, GABAPENTIN, LOPERAMIDE HYDROCHLORIDE, INSULIN GLARGINE, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, INSULIN ASPART, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, PANTOPRAZOLE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, VITAMIN C, ERGOCALCIFEROL, LOSARTAN, SPIRONOLACTONE, |
||||
| 213 | 25136335 |
US |
2 | |
Product dose omission issue, |
||||
BELIMUMAB, |
||||
| 214 | 25136394 |
72 | ||
Product dose omission issue, Critical illness, |
||||
RUXOLITINIB, |
||||
| 215 | 25136439 |
US |
||
Product dose omission issue, |
||||
NORETHINDRONE ACETATE/ETHINYL ESTRADIOL AND FERROUS FUMARATE, |
||||
| 216 | 25136450 |
US |
1 | |
Product dose omission issue, Gait disturbance, Swelling, |
||||
SECUKINUMAB, |
||||
| 217 | 25136484 |
US |
||
Product dose omission issue, No adverse event, |
||||
PEMBROLIZUMAB, |
||||
| 218 | 25136640 |
US |
1 | |
Inflammatory bowel disease, Joint swelling, Blood creatinine increased, White blood cell count decreased, Injection site mass, Product dose omission issue, Product use issue, Injection site pain, Injection site erythema, Insomnia, Pruritus, |
||||
TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, INFLIXIMAB-DYYB, |
||||
| 219 | 25136793 |
US |
1 | |
Accidental exposure to product, Product dose omission issue, Device issue, |
||||
SECUKINUMAB, |
||||
| 220 | 25136804 |
US |
2 | |
Dyspnoea, Diarrhoea, Product dose omission issue, Expired product administered, |
||||
| 221 | 25136859 |
US |
2 | |
Emotional distress, Confusional state, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 222 | 25137047 |
KW |
||
Product availability issue, Product dose omission issue, Haematuria, Fatigue, |
||||
PEGCETACOPLAN, PEGCETACOPLAN, |
||||
| 223 | 25126278 |
US |
37 | 2 |
Product dose omission issue, Product use issue, |
||||
ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE, |
||||
| 224 | 25126288 |
PT |
91 | |
Product dose omission issue, Drug delivery system issue, Device issue, |
||||
| 225 | 25126333 |
US |
42 | 1 |
Rash, Product dose omission issue, |
||||
DUPILUMAB, LORATADINE, LORATADINE TABLET, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, |
||||
| 226 | 25126345 |
US |
2 | |
Product dose omission issue, |
||||
USTEKINUMAB, USTEKINUMAB, |
||||
| 227 | 25126362 |
US |
||
Product dose omission issue, Visual impairment, Device delivery system issue, |
||||
| 228 | 25126372 |
US |
36 | 2 |
Product dose omission issue, |
||||
MACITENTAN, |
||||
| 229 | 25126412 |
US |
||
Sinusitis, Product dose omission issue, Wrong technique in product usage process, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 230 | 25126413 |
US |
60 | 2 |
Pneumonia, Drug ineffective, Product dose omission issue, |
||||
ABATACEPT, |
||||
| 231 | 25126417 |
US |
26 | 1 |
Product dose omission issue, |
||||
CABOTEGRAVIR, |
||||
| 232 | 25126429 |
US |
79 | 2 |
Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 233 | 25126449 |
US |
46 | 1 |
Product dose omission issue, |
||||
GUSELKUMAB, |
||||
| 234 | 25126467 |
US |
2 | |
Headache, Dizziness, Hypertension, Dyspnoea, Dyspnoea exertional, Inappropriate schedule of product administration, Product dose omission issue, |
||||
TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, TREPROSTINIL, NINTEDANIB, NINTEDANIB, SILDENAFIL CITRATE, SILDENAFIL, OXYGEN, 0XYGEN, OXYGEN, 0XYGEN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 235 | 25126477 |
US |
25 | 1 |
Migraine, Product dose omission issue, Injection site pruritus, Injection site pain, |
||||
GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, GALCANEZUMAB-GNLM, |
||||
| 236 | 25126519 |
US |
25 | 1 |
Device issue, Product dose omission issue, Contusion, |
||||
GUSELKUMAB, |
||||
| 237 | 25126594 |
US |
74 | |
Product dose omission issue, Injury associated with device, |
||||
BENRALIZUMAB, |
||||
| 238 | 25126608 |
US |
52 | 2 |
Incorrect dose administered, Product dose omission issue, |
||||
TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE, |
||||
| 239 | 25126622 |
US |
||
Product quality issue, Product dose omission issue, Incorrect dose administered by device, |
||||
PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, |
||||
| 240 | 25126625 |
US |
2 | |
Product dose omission issue, |
||||
PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, PALIPERIDONE PALMITATE, |
||||
| 241 | 25126627 |
US |
51 | 1 |
Product dose omission issue, |
||||
CABOTEGRAVIR, CABOTEGRAVIR, CABOTEGRAVIR, |
||||
| 242 | 25126666 |
US |
||
Dyspnoea, Intentional product use issue, Product dose omission issue, Wrong technique in product usage process, Device malfunction, |
||||
BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, |
||||
| 243 | 25126796 |
GB |
33 | 2 |
Ankylosing spondylitis, Cellulitis, Product dose omission issue, |
||||
GOLIMUMAB, |
||||
| 244 | 25126830 |
US |
70 | 2 |
Product dose omission issue, |
||||
LENALIDOMIDE, |
||||
| 245 | 25126901 |
US |
2 | |
Staphylococcal infection, Product dose omission issue, Insurance issue, |
||||
BIMEKIZUMAB, |
||||
| 246 | 25126908 |
US |
21 | 2 |
Psoriasis, Product dose omission issue, |
||||
BIMEKIZUMAB, FEXOFENADINE HYDROCHLORIDE, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 247 | 25126920 |
US |
45 | 2 |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 248 | 25126926 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 249 | 25126929 |
US |
2 | |
Product use issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 250 | 25126938 |
US |
61 | 1 |
Product dose omission issue, |
||||
ABACAVIR SULFATE, DOLUTEGRAVIR SODIUM, LAMIVUDINE, |
||||
| 251 | 25126947 |
US |
43 | 2 |
Product dose omission issue, Device issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, IXEKIZUMAB, |
||||
| 252 | 25126948 |
US |
64 | 2 |
Influenza like illness, Product dose omission issue, |
||||
BIMEKIZUMAB, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 253 | 25126949 |
US |
1 | |
Product dose omission issue, Product knowledge deficit, |
||||
BIMEKIZUMAB, |
||||
| 254 | 25126951 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 255 | 25126956 |
US |
1 | |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 256 | 25126957 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 257 | 25126959 |
US |
19 | 2 |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 258 | 25126964 |
US |
2 | |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 259 | 25126974 |
US |
2 | |
Injection site swelling, Infection, Drug ineffective, Product dose omission issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, CETIRIZINE HYDROCHLORIDE, |
||||
| 260 | 25126978 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 261 | 25126983 |
US |
||
Product dose omission issue, Device malfunction, |
||||
BIMEKIZUMAB, |
||||
| 262 | 25127007 |
US |
2 | |
Product dose omission issue, Insurance issue, |
||||
BIMEKIZUMAB, |
||||
| 263 | 25127008 |
US |
1 | |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 264 | 25127016 |
US |
1 | |
Device failure, Product dose omission issue, Off label use, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 265 | 25127024 |
US |
2 | |
Pruritus, Product dose omission issue, |
||||
BIMEKIZUMAB, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, CELECOXIB, |
||||
| 266 | 25127037 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 267 | 25127045 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 268 | 25127062 |
US |
2 | |
Condition aggravated, Product dose omission issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 269 | 25127086 |
US |
1 | |
Psoriasis, Product dose omission issue, Condition aggravated, Insurance issue, |
||||
BIMEKIZUMAB, |
||||
| 270 | 25127096 |
US |
1 | |
Influenza, Product dose omission issue, Insurance issue, Product availability issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 271 | 25127117 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 272 | 25127121 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 273 | 25127127 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 274 | 25127135 |
US |
23 | 2 |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 275 | 25127137 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 276 | 25127141 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 277 | 25127150 |
US |
34 | 1 |
Product dose omission issue, |
||||
DOLUTEGRAVIR SODIUM AND LAMIVUDINE, |
||||
| 278 | 25127151 |
US |
1 | |
Product dose omission issue, Product administration error, |
||||
BIMEKIZUMAB, |
||||
| 279 | 25127152 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 280 | 25127153 |
US |
1 | |
Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 281 | 25127157 |
US |
1 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 282 | 25127160 |
US |
1 | |
Product dose omission issue, |
||||
CABOTEGRAVIR, CABOTEGRAVIR, CABOTEGRAVIR, |
||||
| 283 | 25127193 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 284 | 25127197 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 285 | 25127199 |
US |
46 | 1 |
Device issue, Product dose omission issue, |
||||
BIMEKIZUMAB, SECUKINUMAB, |
||||
| 286 | 25127204 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 287 | 25127210 |
US |
1 | |
Product dose omission issue, Product availability issue, |
||||
BIMEKIZUMAB, |
||||
| 288 | 25127222 |
US |
1 | |
Product storage error, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 289 | 25127223 |
US |
2 | |
Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 290 | 25127233 |
US |
1 | |
Rash, Product availability issue, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 291 | 25127234 |
US |
1 | |
Loss of personal independence in daily activities, Drug ineffective, Product dose omission issue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 292 | 25127254 |
US |
2 | |
Product dose omission issue, Pruritus, |
||||
BIMEKIZUMAB, |
||||
| 293 | 25127258 |
US |
2 | |
Hidradenitis, Memory impairment, Product dose omission issue, |
||||
BIMEKIZUMAB, ETONOGESTREL, |
||||
| 294 | 25127371 |
US |
43 | 1 |
No adverse event, Accidental underdose, Device use error, Product dose omission issue, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 295 | 25127420 |
US |
62 | 1 |
Product dose omission issue, |
||||
LENALIDOMIDE, |
||||
| 296 | 25127421 |
US |
39 | 2 |
Device operational issue, Device delivery system issue, Product dose omission issue, |
||||
ABATACEPT, |
||||
| 297 | 25127432 |
US |
2 | |
Product dose omission issue, Device mechanical issue, Incorrect dose administered, |
||||
TERIPARATIDE, |
||||
| 298 | 25127450 |
US |
2 | |
Product dose omission issue, Product packaging quantity issue, |
||||
BRIMONIDINE, BRIMONIDINE TARTRATE, |
||||
| 299 | 25127461 |
US |
2 | |
Product storage error, Product dose omission issue, Rash, |
||||
GUSELKUMAB, |
||||
| 300 | 25127490 |
US |
52 | 2 |
Migraine, Product dose omission issue, |
||||
GALCANEZUMAB-GNLM, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28